FDA Panel to Review Peptide Compounding Amid Industry Push and Safety Concerns

The Food and Drug Administration’s Pharmacy Compounding Advisory Committee (PCAD) will convene on July 23 and July 24, 2026 to evaluate whether seven peptide compounds—BPC-157, KPV, TB-500, MOTS-c, Emideltide (DSIP), Semax and Epitalon—should be eligible for compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act. A positive recommendation could reverse a 2023 rule that barred nearly 20 peptides from compounding.

FDA Advisory Committee Convenes on Peptides This Week, Understanding What Reclassification Mean

In 2023 the Biden administration placed roughly 20 peptides in Category 2 of the 503A bulk-drug list, citing safety risks and a lack of human data. Between mid-April 2026 the FDA removed twelve peptide bulk substances from Category 2, creating a regulatory gap that industry groups say fuels a “gray market.” The GLP-1 boom for weight-loss drugs has familiarized patients with at-home injections, prompting telehealth platforms and compounding pharmacies to prepare for broader peptide access.

FDA Panel to Revisit Biden Peptide Ban as It Weighs Looser Rules

• Peptides under review: BPC-157, TB-500, KPV, MOTS-c, Emideltide, Semax, Epitalon.

Forbes

• Public input: Nearly 1,900 comments and expert testimonies have been submitted.

FDA Panel to Revisit Biden Peptide Ban as It Weighs Looser Rules

• Market scale: More than 20 million doses of the nominated peptides were dispensed or administered in the past eight years, supporting a multibillion-dollar industry.

FDA Panel to Revisit Biden Peptide Ban as It Weighs Looser Rules

Lee Rosebush, chairman of the American Academy of Peptide Medicine, expressed optimism that the review would be impartial. Edwin Lee, co-founder of the Clinical Peptide Society, emphasized that peptides should be obtained only through licensed compounding pharmacies inspected by state boards and the FDA. Dr. Gurpreet Padda of Regen MD warned patients against interpreting “reclassification” as FDA approval.

FDA Panel to Revisit Biden Peptide Ban as It Weighs Looser Rules

Independent safety groups counter that no rigorous randomized controlled human trials exist for any of the seven compounds, leaving dosing, long-term risks and benefit-risk balances unknown. The panel’s composition remains contentious: new members were added after criticism of conflicts of interest, yet observers note that the panel still includes individuals linked to peptide-related businesses.

Forbes

• “We’re getting everything ready to go,” — Myra Ahmad, chief executive of the telehealth platform Mochi Health

Wired Magazine

• “I remain hopeful that the process will be fair and free of conflicts, and that recommendations will be formed based on the merits,” — Lee Rosebush

FDA Adds More Peptide Panel Experts After Conflict Criticism (1)

The PCAD’s recommendations are advisory; any change to the 503A bulk-drug list would require formal notice-and-comment rulemaking before becoming law. A subsequent PCAD session is scheduled before the end of February 2027 to consider five additional compounds, including GHK-Cu and Melanotan II. Stakeholders anticipate that the outcome of the July 23-24 meeting will shape the regulatory landscape for peptide therapies for years to come.

FDA Advisory Committee Convenes on Peptides This Week, Understanding What Reclassification Mean